These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 349320)

  • 1. Hyperkinesis and diet: a double-blind crossover trial with a tartrazine challenge.
    Levy F; Dumbrell S; Hobbes G; Ryan M; Wilton N; Woodhill JM
    Med J Aust; 1978 Jan; 1(2):61-4. PubMed ID: 349320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative effects of drugs and diet on hyperactive behaviors: an experimental study.
    Williams JI; Cram DM; Tausig FT; Webster E
    Pediatrics; 1978 Jun; 61(6):811-7. PubMed ID: 353680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic food colors and hyperactivity in children: a double-blind challenge experiment.
    Harley JP; Matthews CG; Eichman P
    Pediatrics; 1978 Dec; 62(6):975-83. PubMed ID: 366539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperkinesis and food additives: testing the Feingold hypothesis.
    Harley JP; Ray RS; Tomasi L; Eichman PL; Matthews CG; Chun R; Cleeland CS; Traisman E
    Pediatrics; 1978 Jun; 61(6):818-28. PubMed ID: 353681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Favourable effect of a standard elimination diet on the behavior of young children with attention deficit hyperactivity disorder (ADHD): a pilot study].
    Pelsser LM; Buitelaar JK
    Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2543-7. PubMed ID: 12532668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.
    Wasserman S; Iyengar R; Chaplin WF; Watner D; Waldoks SE; Anagnostou E; Soorya L; Hollander E
    Int Clin Psychopharmacol; 2006 Nov; 21(6):363-7. PubMed ID: 17012983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic food colourings and 'hyperactivity': a double-blind crossover study.
    Rowe KS
    Aust Paediatr J; 1988 Apr; 24(2):143-7. PubMed ID: 3395307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonidine treatment of hyperactive and impulsive children with autistic disorder.
    Jaselskis CA; Cook EH; Fletcher KE; Leventhal BL
    J Clin Psychopharmacol; 1992 Oct; 12(5):322-7. PubMed ID: 1479049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label use of placebos in the treatment of ADHD: a pilot study.
    Sandler AD; Bodfish JW
    Child Care Health Dev; 2008 Jan; 34(1):104-10. PubMed ID: 18171451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between the WISC-III and the Cognitive Assessment System with Conners' rating scales and continuous performance tests.
    Naglieri JA; Goldstein S; Delauder BY; Schwebach A
    Arch Clin Neuropsychol; 2005 May; 20(3):385-401. PubMed ID: 15797174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
    Biederman J; Gao H; Rogers AK; Spencer TJ
    Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled, randomized, double-blind trial to evaluate the effect of a supplement of cocoa husk that is rich in dietary fiber on colonic transit in constipated pediatric patients.
    Castillejo G; Bulló M; Anguera A; Escribano J; Salas-Salvadó J
    Pediatrics; 2006 Sep; 118(3):e641-8. PubMed ID: 16950955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW; Earl CQ; Arora S
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutrient intakes of children on the hyperkinesis diet.
    Harper PH; Goyette CH; Conners CK
    J Am Diet Assoc; 1978 Nov; 73(5):515-9. PubMed ID: 701681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Double-blind, placebo-controlled cow's milk challenge in children with alleged cow's milk allergies, performed in a general hospital: diagnosis rejected in two-thirds of the children].
    Hospers IC; de Vries-Vrolijk K; Brand PL
    Ned Tijdschr Geneeskd; 2006 Jun; 150(23):1292-7. PubMed ID: 16821454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study.
    Cubo E; Fernández Jaén A; Moreno C; Anaya B; González M; Kompoliti K
    Clin Ther; 2008 Jan; 30(1):182-9. PubMed ID: 18343255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.